Risk factors for mortality in patients with cardiac device-related infection

Circulation: Arrhythmia and Electrophysiology

Volumn 2, Issue 2, 2009, Pages 129-134

  Baman, Timir S ^a   Gupta, Sanjaya K ^a   Valle, Javier A ^a   Yamada, Elina ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Cardiovascular Center   (United States)

Author keywords

Infection; Mortality; Outcome assessment; Risk factors

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL EXAMINATION; DEFIBRILLATOR; DEVICE INFECTION; ECHOCARDIOGRAPHY; EMBOLISM; FEMALE; HEART RIGHT VENTRICLE FUNCTION; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; TRICUSPID VALVE REGURGITATION;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; AGED, 80 AND OVER; ARRHYTHMIAS, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; MALE; MICHIGAN; MORBIDITY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PACEMAKER, ARTIFICIAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTHESIS-RELATED INFECTIONS; PULMONARY EMBOLISM; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 70349469829     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.108.816868     Document Type: Article

References (30)

1. Parsonnet V, Zucker R, Gilbert L, Myers GH. Clinical use of an implantable standby pacemaker. JAMA. 1966; 196:784 -786.
2. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005; 352:1539 -1549. (Pubitemid 40517094)
3. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM. Cardiac- resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004; 350: 2140-2150.
4. Moss AJ, Fadl Y, Zareba W, Cannom DS, Hall WJ. Survival benefit with an implanted defibrillator in relation to mortality risk in chronic coronary heart disease. Am J Cardiol. 2001; 88:516 -520.
5. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002; 346:877- 883.
6. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med. 1999; 341:1882-1890.
7. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp- Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005; 352:225-237.
8. Frame R, Brodman RF, Furman S, Andrews CA, Gross JN. Surgical removal of infected transvenous pacemaker leads. Pacing Clin Electrophysiol. 1993; 16:2343-2348.
9. Kearney RA, Eisen HJ, Wolf JE. Nonvalvular infections of the cardiovascular system. Ann Intern Med. 1994; 121:219 -230.
10. Lai KK, Fontecchio SA. Infections associated with implantable cardioverter defibrillators placed transvenously and via thoracotomies: epidemiology, infection control, and management. Clin Infect Dis. 1998; 27:265-269.
11. Trappe HJ, Pfitzner P, Klein H, Wenzlaff P. Infections after cardioverterdefibrillator implantation: observations in 335 patients over 10 years. Br Heart J. 1995; 73:20 -34.
12. Klug D, Balde M, Pavin D, Hidden-Lucet F, Clementy J, Sadoul N, Rey JL, Lande G, Lazarus A, Victor J, Barnay C, Grandbastien B, Kacet S. Risk factors related to infections of implanted pacemakers and cardioverterdefibrillators: results of a large prospective study. Circulation. 2007; 116: 1349-1355.
13. Voigt A, Shalaby A, Saba S. Rising rates of cardiac rhythm management device infections in the United States: 1996 through 2003. J Am Coll Cardiol. 2006; 48:590 -591.
14. Catanchin A, Murdock CJ, Athan E. Pacemaker infections: a 10-year experience. Heart Lung Circ. 2007; 16:434-439.
15. Villamil Cajoto I, Rodrí guez Framil M, Van den Eynde Collado A, José Villacián Vicedo M, Canedo Romero C. Permanent transvenous pacemaker infections: an analysis of 59 cases. Eur J Intern Med. 2007; 18:484-488.
16. Sohail MR, Uslan DZ, Khan AH, Friedman PA, Hayes DL, Wilson WR, Steckelberg JM, Stoner S, Baddour LM. Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections. J Am Coll Cardiol. 2007; 49:1851-1859.
17. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Am J Med. 1994; 96:200 -219.
18. Uslan DZ, Sohail MR, Friedman PA, Hayes DL, Wilson WR, Steckelberg JM, Baddour LM. Frequency of permanent pacemaker or implantable cardioverter- defibrillator infection in patients with gram-negative bacteremia. Clin Infect Dis. 2006; 43:731-736.
19. Vilacosta I, Graupner C, San Román JA, Sarriá C, Ronderos R, Fernández C, Mancini L, Sanz O, Sanmartí n JV, Stoermann W. Risk of embolization after institution of antibiotic therapy for infective endocarditis. J Am Coll Cardiol. 2002; 39:1489 -1495.
20. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, Nihoyannopoulos P, Otto CM, Quinones MA, Rakowski H, Stewart WJ, Waggoner A, Weissman NJ; American Society of Echocardiography. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003; 16:777- 802.
21. National Death Index User's Manual. Hyattsville, MD: Department of Vital Statistics, Centers for Disease Control; 2003.
22. Calle EE, Terrell DD. Utility of the National Death Index for ascertainment of mortality among cancer prevention study II participants. Am J Epidemiol. 1993; 137:235-241.
23. Sohail MR, Uslan DZ, Khan AH, Friedman PA, Hayes DL, Wilson WR, Steckelberg JM, Stoner SM, Baddour LM. Risk factor analysis of permanent pacemaker infection. Clin Infect Dis. 2007; 45:166 -173.
24. Bloom H, Heeke B, Leon A, Mera F, Delurgio D, Beshai J, Langberg J. Renal insufficiency and the risk of infection from pacemaker or defibrillator surgery. Pacing Clin Electrophysiol. 2006; 29:142-155.
25. Gibson NS, Sohne M, Buller HR. Prognostic value of echocardiography and spiral computed tomography in patients with pulmonary embolism. Curr Opin Pulm Med. 2005; 11:380 -394.
26. Come PC. Echocardiographic evaluation of pulmonary embolism and its response to therapeutic interventions. Chest. 1992; 101:151S-162S.
27. Klug D, Lacroix D, Savoye C, Goullard L, Grandmougin D, Hennequin JL, Kacet S, Lekieffre J. Systemic infection related to endocarditis on pacemaker leads. Circulation. 1997;95:2098 -2107.
28. Hecht SR, Berger M. Right-sided endocarditis in intravenous drug users. Prognostic features in 102 episodes. Ann Intern Med. 1992; 117:560 -566.
29. Martí n-Dávila P, Navas E, Fortún J, Moya JL, Cobo J, Pintado V, Quereda C, Jiménez-Mena M, Moreno S. Analysis of mortality and risk factors associated with native valve endocarditis in drug users: the importance of vegetation size. Am Heart J. 2005; 150:1099 -1106.
30. Kupferwasser LI, Hafner G, Mohr-Kahaly S, Erbel R, Meyer J, Darius H. The presence of infection-related antiphospholipid antibodies in infective endocarditis determines a major risk factor for embolic events. J Am Coll Cardiol. 1999; 33:1365-1371.